

Lytix Biopharma to host Capital Markets Day

Save the date; November 22, 2022

The topic will be the versatility of our technology platform and further outlook for the clinical program



Niels Junker,
Chief Physician
at Herlev Hospital



Aurelien Marabelle,
Professor of Clinical
Immunology, Université
Paris Saclay



Stephen Worsley,
CBO, Lytix



Øystein Rekdal,
CEO, Lytix

- Lytix Biopharma is pleased to announce that it will host a Capital Markets Day for investors, analysts and media Tuesday, November 22, 2022.
- Speakers will be
 - Niels Junker, Chief Physician at Herlev Hospital and investigator at the ATLAS-IT-04 proof-of-concept study
 - Aurelien Marabelle, Professor of Clinical Immunology, Université Paris Saclay and an internationally recognized expert on intratumoral cancer treatment
 - Stephen Worsley, CBO of Lytix
 - Øystein Rekdal, CEO of Lytix
- Lytix has established collaborations with world leading researchers and scientists. The innovative technology platform created at Lytix stands out as unique in the clinical and commercial field of immunology (IO). It differentiates itself from other IO therapeutic categories and presents drug candidates that are ideal combination partners for immune checkpoint inhibitors and T-cell therapy.
- The event will be open for physical attendance in Oslo, Norway, and as a live webcast. It is scheduled to start at 14.30 CET, and is expected to last approximately two hours, including Q&A.
- The management team will be available at the event.
- Further details of the agenda and registration details will follow.

Lytix Biopharma is a Norwegian immune-oncology company with a first-in-class technology platform and candidate drugs candidates in two independent Phase II clinical trials, supported by firm scientific, commercial and financial validation.

